Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SOPHOS: PT009 vs PT005 in Moderate to Very Severe COPD
NCT02727660Phase 3Completed
- Sponsor
- Pearl Therapeutics
- Start
- Apr 2016
- Primary completion
- Apr 2018
- Modality
- Orthosteric Ligands
- Countries
- 19
01
Overview
A Phase 3 trial of budesonide, formoterol fumarate in chronic obstructive pulmonary disease (COPD), sponsored by Pearl Therapeutics. Started Apr 2016; status: completed.
02
Drugs
budesonideformoterol fumarate
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on NCT02727660.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02727660.